AHRQ offers ‘snapshots’ into states’ progress on care quality

Laura Pedulli | | Health Exec | Economics

The Agency for Healthcare Research and Quality has published ‘state snapshots’ that offer insight into states’ progress on the quality of their healthcare delivery.

State Snapshots includes charts on the strengths, weaknesses and opportunities for improvement—and offer data that can be segmented and analyzed by type of care, treatment setting, clinical condition, insurance status, race and income. Moreover, they offer the ability to compare each state’s quality of healthcare delivery with national rates or data from top performing states.

The snapshots utilize data from the 2013 National Healthcare Quality Report and National Healthcare Disparities Report, according to the agency.

To learn more, go here. 

Laura Pedulli

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.